CA 27.29
| Label Mnemonic: | C2729 |
| Epic code: | LAB2769 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen(s):
Serum
Collection Medium:
 |
| Red top tube 5 mL (Clot Activator) |
Minimum:
Recommended Minimum: 1.0 mL serum
Absolute Minimum: 0.5 mL serum
Absolute Minimum: 0.5 mL serum
Rejection Criteria:
Plasma
Turn Around
Time:
24 hours upon receipt at reference laboratory (upon receipt in laboratory)
Reference Range:
0-40 U/mL
Interpretive Data:
The Siemens Advia Centaur CA 27.29 chemiluminescent immunoassay is
used. Results obtained with different assay methods or kits cannot be
used interchangeably. The CA 27.29 assay is intended for use as an aid
in monitoring patients previously treated for Stage II or III breast
cancer. Serial testing in patients who are clinically free of disease
should be used in conjunction with other clinical methods used for the
early detection of cancer recurrence. The test is also intended for
use as an aid in the management of breast cancer patients with
metastatic disease by monitoring the progression or regression of
disease in response to treatment. Patients with confirmed breast
carcinoma frequently have CA 27.29 levels within the reference
interval. Elevated levels of CA 27.29 can be observed in patients with
nonmalignant diseases. Therefore, this result cannot be interpreted as
absolute evidence of the presence or absence of malignant disease and
should always be used in conjunction with other diagnostic procedures,
including information from the patient's clinical evaluation.
Methodology:
Chemiluminescent Immunoassay
CPT Code:
86300